PARP1 and familial pancreatic carcinoma: The combination of niraparib with immunotherapeutic agents targeting PD-1, such as dostarlimab (NCT04493060), dostarlimab plus radiotherapy (NCT04409002), nivolumab, or ipilimumab (anti-CTLA-4) (NCT03404960), are currently under investigation, suggesting that the future of pancreatic cancer treatment could take advantage of novel synergistic approaches of immunotherapy and targeted PARP inhibitors.